Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE CCG Investor Relations
Exciting lineup of life sciences companies to present at free, online conference Thursday, September 12th
Andrew Fein, Senior Biotech Analyst at H.C. Wainwright, will discuss key trends among NexGen Drugs and Global CROs
NEW YORK, Sept. 11, 2013 /PRNewswire/ -- CCG Investor Relations, a leading global investor relations and strategic communications consultancy, is pleased to announce the companies who will present their investment stories as part of the Life Sciences Virtual Investment Conference to be held on Thursday, September 12, 2013.
The NexGen Life Science Virtual Investment Conference is organized by CCG Investor Relations and co-hosted by BetterInvesting, and PR Newswire. The event is designed to provide retail investors, institutional investors, financial advisors and family offices with a road map as to how scientific breakthroughs move through the process towards commercialization, including FDA trials, partnerships, distribution agreements and coverage by health insurance and Medicare.
The virtual conference is free for both retail and institutional investors to attend. To register, please visit http://www.retailinvestorconferences.com/.
Crocker Coulson of CCG Investor Relations will interview Andrew Fein, Managing Director & Senior Analyst at H.C. Wainwright on a panel on NexGen Drugs and Global CROs from 9am to 10am.
The presenting schedule for the conference is as follows:
08:15 a.m. ET: BioLight Israeli Life Sciences Investments Ltd (TASE: BOLT), Suzana Bar-Natan, CEO
09:00 a.m. ET: Analyst Discussion with Andrew Fein: NextGen Drugs and Global CROs
10:15 a.m. ET: Del Mar Pharmaceuticals Inc (OTCBB: DMPI)
11:00 a.m. ET: Organovo (NYSE: ONVO)
11:45 a.m. ET: Bone Biologics
12:30 p.m. ET: Advanced Bifurcation Systems
"A new wave of innovation is sweeping the life sciences sector, creating the opportunity for new therapies that save lives or improve patient care, while offering exceptional returns for investors, who employ thoughtful stock selection," said Crocker Coulson, President of CCG.
"This virtual conference will focus on companies with scientific breakthroughs to develop whole new classes of drugs, devices, therapies and diagnostic procedures. Investors, who are new to life sciences or experts in the field, will obtain a wealth of new investment ideas from the presenting companies. We are very pleased with the line-up of presenting companies and I look forward to a very stimulating conversation with Andrew Fein, a Senior Biotech Analyst and Managing Director at H.C. Wainwright," Coulson said.
These are the descriptions of the presenting companies:
BioLight (TASE: BOLT) directly invests in, manages and commercializes biomedical innovations by focusing on groups, or 'clusters,' of technologies that explore different aspects of the same medical condition. BioLight's two current clusters include ophthalmology, through its 100% owned subsidiary XL Vision; and cancer diagnostics via its 29% ownership of Micromedic (TASE: MCTC).
DelMar Pharmaceuticals (OTC: DMPI) was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
Organovo (NYSE: ONVO) designs and creates functional human tissues using a proprietary three-dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications. The Company's NovoGen™ three-dimensional bioprinting technology employs a specialized automated platform that works across all tissue and cell types. Organovo's bioprinter was named one of the "Best Inventions of 2010" by TIME Magazine and Organovo has been recognized as one of the most innovative companies of 2012 by MIT's Technology Review. Organovo is helping pharmaceutical partners develop never before available human biological disease models in three dimensions that hold the potential to transform the business of therapeutic drug discovery and development. Organovo is also developing direct tissue therapies where precise structure and architecture may deliver the best clinical outcomes. Organovo leads the way in solving complex medical research problems and building the future of medicine.
Bone Biologics was founded by University of California professors in collaboration with an Osaka University professor and a USC Surgeon in 2004. Bone Biologics is a privately-held company with proprietary, patented technology that has been clinically proven in non-human primate models to facilitate bone growth. The company is currently focused on bone regeneration in spinal fusion using its recombinant human protein, known as UCB-1 (or Nell-1). UCB-1 is an osteoinductive orthobiologic: a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA.
Advanced Bifurcation Systems (ABS) has developed a novel technology to enable effective stenting of coronary arteries at their branch points (bifurcations). Every year millions of patients around the world with heart disease present to doctors who find they are faced with either a PCI or CABG procedure. A quarter of those requiring stenting will have bifurcation lesions, meaning a build-up of plaque that is blocking or about to block blood flow to the heart at a place where the blood vessel divides in two. ABS was founded in late 2008 with the vision to facilitate the stenting of bifurcation disease so that its percutaneous treatment becomes the standard of care at bifurcated lesions.
About CCG Investor Relations
CCG is one of the nation's leading investor relations and strategic communications agencies. In business for more than 30 years, the agency provides a complete range of investor communications and counseling services to nearly 30 clients across multiple capital markets. CCG has been awarded a number of industry honors for its handling of complex investor relations and crisis communications matters. The agency's corporate headquarters is in New York with additional offices in Los Angeles, Beijing, Frankfurt, and Tel Aviv. For further information, contact CCG directly, or visit the Company's websites at http://www.ccgir.com and http://www.ccgirasia.com.
About PR Newswire
PR Newswire is the premier global provider of multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry 59 years ago, PR Newswire today provides end-to-end solutions to produce, optimize and target content - from rich media to online video to multimedia - and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world's enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a UBM plc company. Visit the company website http://www.prnewswire.com/ for more details.
BetterInvesting has helped over 5 million people become better, more informed investors. We help our members build wealth through educational webinars, web-based mutual fund and stock tools, in-person learning events, publications, an active online community and software. Its mission investment is to provide a sound program of information, education, and support that helps create successful lifetime investors. By becoming confident, knowledgeable investors, our members are empowered to build better financial futures for themselves and their families. BetterInvesting has an extensive and active retail investor constituency that actively investment information and new investment ideas.
For more information about The NexGen Life Sciences Virtual Conference please contact:
Crocker Coulson, President
CCG Investor Relations
Direct: +1 646-213-1915
©2012 PR Newswire. All Rights Reserved.